{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T19:56:04Z","timestamp":1795118164116,"version":"4.10.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100009155","name":"Otsuka America Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009155","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lundbeck LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12888-017-1213-6","type":"journal-article","created":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T07:47:31Z","timestamp":1486972051000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications"],"prefix":"10.1186","volume":"17","author":[{"given":"Pierre-Michel","family":"Llorca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Lan\u00e7on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Hartry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Michelle","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana B.","family":"DiBenedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhesh A.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,13]]},"reference":[{"issue":"2 Suppl","key":"1213_CR1","first-page":"1","volume":"161","author":"AF Lehman","year":"2004","unstructured":"Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1\u201356.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"1213_CR2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","volume":"25","author":"TR Barnes","year":"2011","unstructured":"Barnes TR, Schizophrenia Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(5):567\u2013620.","journal-title":"J Psychopharmacol"},{"key":"1213_CR3","unstructured":"National Collaborating Centre for Mental Health. Psychosis and schizophrenia in adults: treatment and management. 2015. https:\/\/www.nice.org.uk\/guidance\/cg178\/evidence . Accessed 1 Feb 2017."},{"issue":"3","key":"1213_CR4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/15622975.2013.770551","volume":"14","author":"H Grunze","year":"2013","unstructured":"Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, M\u00f6ller HJ, Kasper S. WFSBP task force on treatment guidelines for bipolar disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154\u2013219.","journal-title":"World J Biol Psychiatry"},{"key":"1213_CR5","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0140-6736(13)60857-0","volume":"381","author":"JR Geddes","year":"2013","unstructured":"Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381:1672\u201382.","journal-title":"Lancet"},{"issue":"5","key":"1213_CR6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881115581093","volume":"29","author":"A Cleare","year":"2015","unstructured":"Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459\u2013525.","journal-title":"J Psychopharmacol"},{"key":"1213_CR7","unstructured":"Work Group on Major Depressive Disorder. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. 2010. http:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/mdd.pdf . Accessed 1 Feb 2017."},{"issue":"7","key":"1213_CR8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.eurpsy.2004.06.031","volume":"19","author":"M Lambert","year":"2004","unstructured":"Lambert M, Conus P, Eide P, et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry. 2004;19(7):415\u201322.","journal-title":"Eur Psychiatry"},{"issue":"suppl 1","key":"1213_CR9","first-page":"273","volume":"26","author":"J Pakpoor","year":"2014","unstructured":"Pakpoor J, Agius M. A review of the adverse side effects associated with antipsychotics as related to their efficacy. Psychiatr Danub. 2014;26 suppl 1:273\u201384.","journal-title":"Psychiatr Danub"},{"issue":"3","key":"1213_CR10","doi-asserted-by":"crossref","first-page":"e1001403","DOI":"10.1371\/journal.pmed.1001403","volume":"10","author":"GI Spielmans","year":"2013","unstructured":"Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. Plos Med. 2013;10(3):e1001403.","journal-title":"Plos Med"},{"issue":"12","key":"1213_CR11","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1517\/14656560903061309","volume":"10","author":"J Volavka","year":"2009","unstructured":"Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10(12):1917\u201328.","journal-title":"Expert Opin Pharmacother"},{"issue":"9896","key":"1213_CR12","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani L, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362.","journal-title":"Lancet"},{"key":"1213_CR13","unstructured":"National Institute of Mental Health. Numbers count: mental disorders in America. Bethesda, MD, 2013. http:\/\/www.lb7.uscourts.gov\/documents\/12-cv-1072url2.pdf . Accessed 1 Feb 2017."},{"key":"1213_CR14","unstructured":"US Census Bureau. Age and sex composition: 2010 (C2010BR-03). Washington: US Census Bureau; 2011. http:\/\/www.census.gov\/prod\/cen2010\/briefs\/c2010br-03.pdf . Accessed 1 Feb 2017."},{"key":"1213_CR15","unstructured":"Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Mental Health Findings. Rockville, MD, 2014. http:\/\/www.samhsa.gov\/data\/sites\/default\/files\/NSDUHmhfr2013\/NSDUHmhfr2013.pdf . Accessed 1 Feb 2017."},{"issue":"11","key":"1213_CR16","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1517\/14656566.2012.656590","volume":"13","author":"DS Cha","year":"2012","unstructured":"Cha DS, McIntyre RS. Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother. 2012;13(11):1587\u201398.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1213_CR17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/j.2051-5545.2008.tb00154.x","volume":"7","author":"A Ucok","year":"2008","unstructured":"Ucok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry. 2008;7(1):58\u201362.","journal-title":"World Psychiatry"},{"key":"1213_CR18","unstructured":"US Department of Health and Human Services Food and Drug Administration. Patient preference information\u2014submission, review in PMAs, HDE applications, and de novo requests, and Inclusion in device labeling: Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. 2015. http:\/\/www.fda.gov\/downloads\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/UCM446680.pdf . Accessed 1 Feb 2017."},{"key":"1213_CR19","doi-asserted-by":"crossref","first-page":"s64","DOI":"10.1192\/bjp.191.50.s64","volume":"50","author":"S Hamer","year":"2007","unstructured":"Hamer S, Haddad PM. Adverse effects of antipsychotics as outcome measures. Br J Psychiatry Suppl. 2007;50:s64\u201370.","journal-title":"Br J Psychiatry Suppl"},{"issue":"50","key":"1213_CR20","first-page":"1188","volume":"28","author":"V Welch","year":"2001","unstructured":"Welch V, Singh G, Strand V, et al. Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford toxicity index. J Rheumatol. 2001;28(50):1188\u201391.","journal-title":"J Rheumatol"},{"key":"1213_CR21","doi-asserted-by":"crossref","unstructured":"Reeves BB, Mitchell SA, Deuck AC, et al. Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst. 2014;106(7):dju129.","DOI":"10.1093\/jnci\/dju129"},{"issue":"4","key":"1213_CR22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0447.1993.tb03366.x","volume":"87","author":"J Gerlach","year":"1993","unstructured":"Gerlach J, Korsgaard S, Clemmesen P, et al. The St. Hans rating scale for extrapyramidal syndromes: reliability and validity. Acta Psychiat Scand. 1993;87(4):244\u201352.","journal-title":"Acta Psychiat Scand"},{"issue":"2","key":"1213_CR23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00019053-199507020-00006","volume":"7","author":"P Bech","year":"1995","unstructured":"Bech P. Quality-of-life measurements for patients taking which drugs? The clinical PCASEE perspective. Pharmecoeconomics. 1995;7(2):141\u201351.","journal-title":"Pharmecoeconomics"},{"key":"1213_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","volume":"334","author":"O Lingjaerde","year":"1987","unstructured":"Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiat Scand Suppl. 1987;334:1\u2013100.","journal-title":"Acta Psychiat Scand Suppl"},{"issue":"4","key":"1213_CR25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1046\/j.1440-0979.2000.00181.x","volume":"9","author":"P Morrison","year":"2000","unstructured":"Morrison P, Gaskill D, Meehan T, et al. The use of the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) in clinical practice. Aust N Z J Ment Health Nurs. 2000;9(4):166\u201376.","journal-title":"Aust N Z J Ment Health Nurs"},{"key":"1213_CR26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1586\/erp.11.103","volume":"12","author":"CJ Demuro","year":"2012","unstructured":"Demuro CJ, Lewis SA, Dibenedetti DB, et al. Successful implementation of cognitive interviews in special populations. Expert Rev Pharmacoecon Outcomes Res. 2012;12:181\u20137.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"1213_CR27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4306\/pi.2015.12.1.46","volume":"12","author":"GH Oh","year":"2015","unstructured":"Oh GH, Yu J-C, Choi K-S, et al. Simultaneous comparison of efficacy and tolerability of second-generation antipsychotics in schizophrenia: mixed-treatment comparison analysis based on head-to-head trial data. Psychiatry Investig. 2015;12(1):46\u201354.","journal-title":"Psychiatry Investig"},{"issue":"5","key":"1213_CR28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/hup.2332","volume":"28","author":"MS Karthik","year":"2013","unstructured":"Karthik MS, Kulhara P, Chakrabarti S. Attitude towards second-generation antipsychotics among patients with schizophrenia and their relatives. Hum Psychopharmacol. 2013;28(5):457\u201365.","journal-title":"Hum Psychopharmacol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-017-1213-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T06:24:11Z","timestamp":1498371851000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-017-1213-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,13]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1213"],"URL":"https:\/\/doi.org\/10.1186\/s12888-017-1213-6","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,13]]},"article-number":"67"}}